TP53 Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer We evaluated the efficacy and safety of ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
In a new phase 3, double-blind study, researchers explored the efficacy and safety of combination therapy using subcutaneous (SC) belimumab and rituximab for the treatment of active systemic lupus ...
Vielight Neuro RX Gamma device and irradiation configuration used in the randomized, double-blind, sham-controlled trial. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback